SELL: L-selectin
Calcium-dependent lectin that mediates cell adhesion by binding to glycoproteins on neighboring cells.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on SELL, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Antibody 1
| Rivipansel | Phase 3 | GlycoMimetics Incorporated | Small molecule | AntagonistLeukocyte adhesion molecule-1 antagonist | 0 |
| Aselizumab | Phase 2 | — | Antibody | InhibitorLeukocyte adhesion molecule-1 inhibitor | 0 |
- Type 2 diabetes mellitus0.37
- Asthma0.30
- Lymphatic system disorder0.29
- Ankylosing spondylitis0.20
- Atrial fibrillation0.19
- Phlebitis0.19
- Thrombophlebitis0.19
- Aging0.14
- Neoplasm0.12
- Chronic obstructive pulmonary disease0.11
- Rheumatoid arthritis0.10
- Systemic lupus erythematosus0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3161, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P14151, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets